What actually drives the PT-141 price in Australia?
The price of a research-grade PT-141 lot is built up from several distinct components, and the analytical portion is often larger than buyers expect. First is synthesis and crude quality: bremelanotide is a cyclic heptapeptide, and cyclisation plus the non-standard residues make the synthesis more demanding than a short linear sequence (PMID:15134289, PMID:17584134). A cleaner crude reduces downstream purification burden but raises upfront cost. Second is preparative purification — the number of reversed-phase HPLC passes required to reach a stated purity threshold directly affects yield and therefore per-milligram price. Third is the analytical release package: each lot characterised by reversed-phase HPLC for purity, by ESI or MALDI-TOF mass spectrometry for identity, plus counterion and water-content determination, carries real instrument and analyst time. Fourth is documentation and traceability — generating a per-lot COA, retaining chromatograms and linking a lot number to sampling records adds overhead that a bargain supplier may simply skip. Finally, Australian buyers factor in local stock holding and tracked domestic dispatch, which shorten transit and simplify record-keeping compared with drop-shipped international parcels. When you compare two PT-141 quotes, the meaningful question is not 'which is cheaper per milligram' but 'which analytical scope and documentation depth does each price include'. A quote that omits mass confirmation, purity method detail or counterion data is not cheaper on a like-for-like basis — it is a different, thinner product. Treating the analytical package as a line item makes cross-supplier comparison rational rather than guesswork, and it is the single most useful discipline a research purchaser can adopt.
How is PT-141 identity confirmed before a lot is priced and released?
Identity confirmation is the analytical foundation beneath any legitimate PT-141 price, because a purity number is meaningless if the molecule is not what the label claims. Bremelanotide is a defined cyclic melanocortin receptor agonist with a known monoisotopic and average mass, so mass spectrometry is the primary identity tool (PMID:31429064, PMID:34436837). Electrospray ionisation (ESI-MS) generates multiply-charged ions whose deconvoluted mass is compared against the theoretical value for the intact cyclic peptide; a match within a tight mass-accuracy window is the first identity criterion. MALDI-TOF offers an orthogonal, predominantly singly-charged confirmation that is useful as an independent cross-check. For sequence-level assurance, tandem mass spectrometry (MS/MS) fragments the molecule and maps the resulting product ions against the expected sequence, which helps distinguish the target from close analogues or deletion sequences. Reversed-phase HPLC retention time relative to a qualified reference standard adds a chromatographic identity dimension: co-elution with a characterised standard supports the assignment, while a retention shift flags a possible substitution. Because bremelanotide is cyclic, analysts also confirm that the expected ring closure is present rather than a linear precursor, since the two share atoms but differ in mass by the water lost on cyclisation. A robust identity section on a COA therefore states the method used, the observed versus theoretical mass, the mass tolerance applied, and whether an orthogonal technique corroborated the result. When a supplier can show all of this, the identity portion of the price reflects genuine analytical assurance; when a COA merely asserts 'bremelanotide' with no supporting spectrum, the buyer is paying for a claim, not a measurement.
What purity specification should a PT-141 COA report?
Purity is the headline analytical figure most closely tied to price, and understanding how it is measured prevents costly misinterpretation. For research-grade PT-141, purity is typically reported as an area-percent value from reversed-phase HPLC with UV detection, most commonly a chromatographic purity of the main peak relative to total integrated peak area. Two method details matter enormously. The first is the detection wavelength and gradient — a purity figure is only comparable between lots run under the same conditions, so a compliant COA states column chemistry, mobile-phase system, gradient and wavelength. The second is peak-purity assessment: using a diode-array detector (DAD), the spectral homogeneity across a peak indicates whether an apparently single peak actually co-elutes with an impurity. A peak that passes a purity-angle-below-threshold test is more trustworthy than a bare area-percent number. Related-substance profiling then identifies and, where possible, characterises individual impurities — truncation sequences, deletion products, oxidation and deamidation variants each have characteristic behaviour on LC-MS. Because higher purity requires more preparative passes and lower yield, a tighter specification raises price; this is the clearest example of analytical scope directly shaping cost. Buyers should also note that HPLC area-percent purity is not the same as peptide content: a lot can be 98% chromatographically pure yet contain substantial counterion and residual water by mass, which is why net peptide content is a separate figure. A transparent PT-141 quote therefore separates chromatographic purity, the method used to derive it, the impurity profile, and net peptide content — four distinct data points that together justify the stated price far better than a single unqualified percentage.
Why do counterion and water content affect the effective PT-141 price?
Two often-overlooked analytical parameters — counterion identity and water content — materially change the real value behind a PT-141 price. Synthetic peptides purified by reversed-phase HPLC are commonly isolated as salts, frequently with trifluoroacetate (TFA) or acetate as the counterion carried over from the mobile phase and purification workflow. That counterion contributes mass, so a milligram of lyophilised powder is not a milligram of peptide. Counterion analysis — for example ion chromatography or a dedicated assay for TFA versus acetate — quantifies this contribution and feeds into the net-peptide-content calculation. Water content, determined by Karl Fischer titration, does the same for residual and bound moisture in a lyophilised cake. A hygroscopic peptide can absorb appreciable water, further diluting the mass of actual peptide per vial. When you combine chromatographic purity, counterion mass and water content, you arrive at net peptide content, which is the parameter that lets two quotes be compared on a genuine peptide-per-dollar basis. A supplier reporting only gross powder mass and a purity percentage leaves the buyer to guess at the salt and water fraction, which can differ substantially between lots and processes. This is why an apparently cheaper PT-141 can be more expensive per unit of characterised peptide once counterion and water are accounted for. A complete COA states the counterion, its approximate mass fraction or the method used, the Karl Fischer water result, and the resulting net peptide content. These figures also matter for reproducibility: consistent counterion and moisture across lots support consistent reconstitution and quantitation in the laboratory, which is itself part of what a fair price buys.
What does the melanocortin-agonist literature tell analysts about PT-141 characterisation?
Reviewing the published record on bremelanotide helps analysts understand which structural and analytical features deserve scrutiny when characterising PT-141 material, and this context underpins a defensible price. Bremelanotide is described in the literature as a synthetic melanocortin receptor agonist derived from the melanocortin peptide family (PMID:15134289, PMID:17584134, PMID:33455598). Its regulatory approval history is documented in the first-approval and drug-monograph literature (PMID:31429064, PMID:34436837, PMID:31893927), which confirms the defined molecular entity that identity testing must match. This matters for analytics because a well-characterised reference molecule allows a laboratory to qualify a reference standard, set a theoretical mass target for MS, and define expected chromatographic behaviour. The pharmacology literature also catalogues the melanocortin receptor system and its genetic variability (PMID:41002740), which is relevant only insofar as it frames why the peptide sequence and ring structure must be verified precisely — a substitution changes the entity being studied. Safety-monitoring publications from the clinical development programme, including ambulatory blood-pressure and broader safety analyses (PMID:27977473, PMID:35147466), are cited here strictly as evidence that bremelanotide is a defined, extensively studied compound whose exact structure is documented, not to imply any research-material outcome. For a purchasing analyst, the practical takeaway is straightforward: the published identity of the molecule sets the analytical acceptance targets, and a supplier whose COA data align with those documented characteristics is providing material that can be traced back to a known entity. This literature-anchored characterisation is part of what separates a rigorously released research lot from an undocumented one, and it is a legitimate component of the price.
How should Australian buyers compare PT-141 quotes and documentation?
A disciplined comparison of PT-141 quotes turns price into a rational decision rather than a gamble. Start by normalising every quote to net peptide content, not powder mass, using the counterion and water-content data described above; if a supplier cannot provide those figures, treat the quote as incomplete. Next, request the per-lot COA and confirm it names the specific lot you would receive rather than a generic template — a genuine document ties a lot number to its own chromatogram and mass spectrum. Check that the purity figure is accompanied by the HPLC method, that identity is supported by an actual mass result against the theoretical value, and that a peak-purity or orthogonal check is present. For Australian research operations, local stock and tracked domestic dispatch simplify chain-of-custody documentation and shorten transit, which reduces the record-keeping burden of imported parcels; this is a practical value factor, distinct from any storage claim. Consider batch consistency too: if you anticipate repeat purchases, a supplier that documents multi-vial and cross-lot consistency lets you build a reproducible workflow, whereas lot-to-lot variability in salt and moisture can quietly undermine quantitation. Finally, weigh the depth of impurity profiling — a lot with characterised related substances gives you more information to interpret unexpected results than a bare purity percentage. When all of these are laid side by side, a modestly higher price backed by full identity, purity, counterion, water and traceability data frequently represents better value per characterised milligram than a cheaper quote with a thin COA. The goal is a like-for-like analytical comparison, made entirely on documentation and research-quality grounds.
Order Pt141 with documentation
If this guide helped you evaluate Pt141 for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Pt141 card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
What does the PT-141 price in Australia actually include?
A research-grade PT-141 price should cover synthesis, preparative HPLC purification, and the analytical release package: reversed-phase HPLC purity, mass-spectrometry identity, counterion and water-content determination, and a per-lot certificate of analysis. Local stock and tracked domestic dispatch also contribute. Compare quotes on net peptide content and documentation depth, not powder mass alone.
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the developmental designation for bremelanotide, a synthetic cyclic melanocortin receptor agonist documented in the published literature (PMID:15134289, PMID:31429064). The two names refer to the same defined molecular entity, which is what identity testing by mass spectrometry and HPLC verifies for each research lot.
Why can two PT-141 quotes differ so much in price?
Differences usually reflect analytical scope, not just margin. A higher purity specification needs more preparative passes and lower yield, and a full COA with mass confirmation, counterion analysis, water content and impurity profiling costs more to produce than an unsupported purity claim. Normalising to net peptide content reveals the true per-milligram comparison.
What analytical data confirms PT-141 identity?
Identity is confirmed by mass spectrometry — ESI-MS deconvoluted mass or MALDI-TOF — compared against the theoretical mass of the cyclic peptide, ideally corroborated by tandem MS sequence mapping and HPLC co-elution with a qualified reference standard. A COA should state the observed versus theoretical mass and the tolerance applied.
Does chromatographic purity tell me how much peptide is in the vial?
No. HPLC area-percent purity measures the main peak relative to total peaks; it does not account for counterion and residual water mass. Net peptide content, derived from purity plus counterion analysis and Karl Fischer water determination, is the figure that reflects actual peptide per vial and enables fair price comparison.
References
- PMID:15134289 — PT-141 Palatin — Curr Opin Investig Drugs — 2004
- PMID:31429064 — Bremelanotide: First Approval — Drugs — 2019
- PMID:34436837 — Bremelanotide — 2012
- PMID:17584134 — Melanocortins in the treatment of male and female sexual dysfunction — Curr Top Med Chem — 2007
- PMID:31893927 — Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder — Ann Pharmacother — 2020
- PMID:33455598 — The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women — CNS Spectr — 2022
- PMID:27977473 — Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide — J Hypertens — 2017
- PMID:35147466 — Safety Profile of Bremelanotide Across the Clinical Development Program — J Womens Health (Larchmt) — 2022
- PMID:41002740 — Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases — Diseases — 2025
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
